Search Results
Search for other papers by Momoe Itsumi in
Google Scholar
PubMed
Search for other papers by Masaki Shiota in
Google Scholar
PubMed
Search for other papers by Akira Yokomizo in
Google Scholar
PubMed
Search for other papers by Eiji Kashiwagi in
Google Scholar
PubMed
Search for other papers by Ario Takeuchi in
Google Scholar
PubMed
Search for other papers by Katsunori Tatsugami in
Google Scholar
PubMed
Search for other papers by Junichi Inokuchi in
Google Scholar
PubMed
Search for other papers by YooHyun Song in
Google Scholar
PubMed
Search for other papers by Takeshi Uchiumi in
Google Scholar
PubMed
Search for other papers by Seiji Naito in
Google Scholar
PubMed
Introduction Prostate cancer is the most common non-cutaneous cancer and the second leading cause of cancer-related death of men in developed countries ( Siegel et al . 2012 ). Prostate-specific antigen (PSA) screening has improved early detection
Search for other papers by Ross S Thomas in
Google Scholar
PubMed
Search for other papers by Naveed Sarwar in
Google Scholar
PubMed
Search for other papers by Fladia Phoenix in
Google Scholar
PubMed
Search for other papers by R Charles Coombes in
Google Scholar
PubMed
Search for other papers by Simak Ali in
Google Scholar
PubMed
cardiovascular system, as well as being significant for certain brain functions ( Couse & Korach 1999 ). Additionally, estrogens stimulate breast cancer progression and ∼70–80% of breast cancers express ERα. The presence of ERα correlates with likelihood of
Search for other papers by Norman G Nicolson in
Google Scholar
PubMed
Search for other papers by Reju Korah in
Google Scholar
PubMed
Search for other papers by Tobias Carling in
Google Scholar
PubMed
Introduction Adrenocortical cancer (ACC) is a rare endocrine tumor with a poor prognosis. Recent estimates put the incidence at around one case per million people per year, with overall 5-year survival around 40% ( Nicolson et al. 2018
Search for other papers by He-jun Zhao in
Google Scholar
PubMed
Search for other papers by Xia Jiang in
Google Scholar
PubMed
Search for other papers by Li-juan Hu in
Google Scholar
PubMed
Search for other papers by Lei Yang in
Google Scholar
PubMed
Search for other papers by Lian-dong Deng in
Google Scholar
PubMed
Search for other papers by Ya-ping Wang in
Google Scholar
PubMed
Search for other papers by Zhi-peng Ren in
Google Scholar
PubMed
Introduction Pancreatic cancer is closely related to diabetes mellitus. Diabetes mellitus is not only a risk factor for pancreatic cancer, but it is also one of the clinical manifestations of pancreatic cancer ( Everhart & Wright 1995 , Chari
Laboratory of Endocrinology-Bone Diseases and
Laboratory J-C Heuson of Breast Cancer Research, Department of Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Rue Heger-Bordet 1, B1000 Brussels, Belgium
Search for other papers by Denis Nonclercq in
Google Scholar
PubMed
Laboratory of Endocrinology-Bone Diseases and
Laboratory J-C Heuson of Breast Cancer Research, Department of Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Rue Heger-Bordet 1, B1000 Brussels, Belgium
Search for other papers by Fabrice Journé in
Google Scholar
PubMed
Laboratory of Endocrinology-Bone Diseases and
Laboratory J-C Heuson of Breast Cancer Research, Department of Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Rue Heger-Bordet 1, B1000 Brussels, Belgium
Search for other papers by Ioanna Laïos in
Google Scholar
PubMed
Laboratory of Endocrinology-Bone Diseases and
Laboratory J-C Heuson of Breast Cancer Research, Department of Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Rue Heger-Bordet 1, B1000 Brussels, Belgium
Search for other papers by Carole Chaboteaux in
Google Scholar
PubMed
Laboratory of Endocrinology-Bone Diseases and
Laboratory J-C Heuson of Breast Cancer Research, Department of Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Rue Heger-Bordet 1, B1000 Brussels, Belgium
Search for other papers by Robert-Alain Toillon in
Google Scholar
PubMed
Laboratory of Endocrinology-Bone Diseases and
Laboratory J-C Heuson of Breast Cancer Research, Department of Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Rue Heger-Bordet 1, B1000 Brussels, Belgium
Search for other papers by Guy Leclercq in
Google Scholar
PubMed
Laboratory of Endocrinology-Bone Diseases and
Laboratory J-C Heuson of Breast Cancer Research, Department of Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Rue Heger-Bordet 1, B1000 Brussels, Belgium
Search for other papers by Guy Laurent in
Google Scholar
PubMed
-expressing breast carcinomas (more than two third of breast malignancies, Early Breast Cancer Trialists’ Collaborative Group 1998 ) is considered to be principally mediated by ERα (henceforth referred to as ER). The intracellular distribution of ER in
Search for other papers by V X Jin in
Google Scholar
PubMed
Search for other papers by H Sun in
Google Scholar
PubMed
Search for other papers by T T Pohar in
Google Scholar
PubMed
Search for other papers by S Liyanarachchi in
Google Scholar
PubMed
Search for other papers by S K Palaniswamy in
Google Scholar
PubMed
Search for other papers by T H-M Huang in
Google Scholar
PubMed
Search for other papers by R V Davuluri in
Google Scholar
PubMed
has been associated with endocrine diseases such as breast and prostate cancers, and the action of ERs is linked to the growth promotion and invasion of breast cancer cells ( Pearce & Jordan 2004 ). ERs modulate the transcription of target genes when
Department of Pathology, New York University School of Medicine, New York, New York 10010, USA
Search for other papers by Shen Gao in
Google Scholar
PubMed
Department of Pathology, New York University School of Medicine, New York, New York 10010, USA
Search for other papers by Hua Wang in
Google Scholar
PubMed
Department of Pathology, New York University School of Medicine, New York, New York 10010, USA
Search for other papers by Peng Lee in
Google Scholar
PubMed
Department of Pathology, New York University School of Medicine, New York, New York 10010, USA
Search for other papers by Jonathan Melamed in
Google Scholar
PubMed
Department of Pathology, New York University School of Medicine, New York, New York 10010, USA
Search for other papers by Caihong X Li in
Google Scholar
PubMed
Department of Pathology, New York University School of Medicine, New York, New York 10010, USA
Search for other papers by Fahao Zhang in
Google Scholar
PubMed
Department of Pathology, New York University School of Medicine, New York, New York 10010, USA
Search for other papers by Hong Wu in
Google Scholar
PubMed
Department of Pathology, New York University School of Medicine, New York, New York 10010, USA
Search for other papers by Liran Zhou in
Google Scholar
PubMed
Department of Pathology, New York University School of Medicine, New York, New York 10010, USA
Search for other papers by Zhengxin Wang in
Google Scholar
PubMed
Introduction Androgens play a pivotal role in maintaining prostate homeostasis ( Denmeade et al. 1996 ) and under abnormal conditions they contribute to the development of prostate cancer ( Bentel & Tilley 1996 , Craft et al
Search for other papers by Silvia Ottaviani in
Google Scholar
PubMed
Search for other papers by Greg N Brooke in
Google Scholar
PubMed
Search for other papers by Ciara O'Hanlon-Brown in
Google Scholar
PubMed
Search for other papers by Jonathan Waxman in
Google Scholar
PubMed
Search for other papers by Simak Ali in
Google Scholar
PubMed
Search for other papers by Laki Buluwela in
Google Scholar
PubMed
Introduction Androgens play a central role in the biology of normal prostate development and prostate cancer progression ( Shen & Abate-Shen 2010 ). These hormones mediate their effects through the action of the androgen receptor (AR), a member of
Department of Pathology Wakayama Medical University, Kimiidera 811-1, Wakayama 641-0012, Japan Department of Rehabilitation Osaka Kawasaki Rehabilitation University, Mizuma 158, Kaizuka City, Osaka 597-0104, Japan Department of Advanced Medical Science Institute of Medical Science, University of Tokyo, Shirokanedai, 4-6-1, Minato-ku, Tokyo 108-8639, Japan
Search for other papers by Misa Nakamura in
Google Scholar
PubMed
Search for other papers by Bo Han in
Google Scholar
PubMed
Search for other papers by Toshihide Nishishita in
Google Scholar
PubMed
Search for other papers by Yanhua Bai in
Google Scholar
PubMed
Search for other papers by Kennichi Kakudo in
Google Scholar
PubMed
Introduction In molecular cancer therapy, the target which is selected and how it is developed for therapy is important. Most target molecules are oncogenes, growth factors, transcription factors, or cytokines involved in signaling pathways, DNA
Search for other papers by Danrong Ye in
Google Scholar
PubMed
Search for other papers by Yang Jiang in
Google Scholar
PubMed
Search for other papers by Yihan Sun in
Google Scholar
PubMed
Search for other papers by Yuefeng Li in
Google Scholar
PubMed
Search for other papers by Yefeng Cai in
Google Scholar
PubMed
Search for other papers by Qingxuan Wang in
Google Scholar
PubMed
Search for other papers by Ouchen Wang in
Google Scholar
PubMed
Search for other papers by Endong Chen in
Google Scholar
PubMed
Search for other papers by Xiaohua Zhang in
Google Scholar
PubMed
United States, approximately 53,990 cases of thyroid cancer were expected to be newly diagnosed in 2018, leading to a projected 2060 deaths ( Siegel et al. 2018 ). In China, it was predicted that there would be approximately 90,000 newly diagnosed